Abstract
Hsp90 is a molecular chaperone with important roles in regulating the function of several proteins with potential pathogenic activity. Because many of these proteins are involved in cancer and neurodegenerative promoting pathways, Hsp90 has emerged as an attractive therapeutic target in these diseases. Molecules that bind to the N-terminal nucleotide pocket of Hsp90 inhibit its activity, and consequently, disrupt client protein function. A number of these inhibitors from several chemical classes are now known, and some are already in clinical trials. This review focuses on the purine class of Hsp90 inhibitors, their discovery through rational design, and on efforts aimed towards their optimization and development into clinically viable drugs for the treatment of cancer. Their potential towards neurodegenerative diseases will also be touched upon.
Keywords: Heat shock protein 90, purine, cancer, neurodegeneration
Current Topics in Medicinal Chemistry
Title: Purine-Scaffold Hsp90 Inhibitors
Volume: 9 Issue: 15
Author(s): Tony Taldone and Gabriela Chiosis
Affiliation:
Keywords: Heat shock protein 90, purine, cancer, neurodegeneration
Abstract: Hsp90 is a molecular chaperone with important roles in regulating the function of several proteins with potential pathogenic activity. Because many of these proteins are involved in cancer and neurodegenerative promoting pathways, Hsp90 has emerged as an attractive therapeutic target in these diseases. Molecules that bind to the N-terminal nucleotide pocket of Hsp90 inhibit its activity, and consequently, disrupt client protein function. A number of these inhibitors from several chemical classes are now known, and some are already in clinical trials. This review focuses on the purine class of Hsp90 inhibitors, their discovery through rational design, and on efforts aimed towards their optimization and development into clinically viable drugs for the treatment of cancer. Their potential towards neurodegenerative diseases will also be touched upon.
Export Options
About this article
Cite this article as:
Taldone Tony and Chiosis Gabriela, Purine-Scaffold Hsp90 Inhibitors, Current Topics in Medicinal Chemistry 2009; 9 (15) . https://dx.doi.org/10.2174/156802609789895737
DOI https://dx.doi.org/10.2174/156802609789895737 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Equibiotic-GI Consumption Improves Intestinal Microbiota in Subjects with Functional Dyspepsia
Current Drug Therapy Bioactive Constituents from an Endophytic Fungus, Penicillium polonicum NFW9, Associated with Taxus fauna
Medicinal Chemistry Transplantation of Pancreatic Islets Immobilized in Alginate-Based Microcapsules: From Animal Studies to Clinical Trials
Micro and Nanosystems Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets Synthesis of Pyrrole-Based Macrocycles as Molecular Probes for Multimodal Imaging Techniques: Recent Trends
Current Organic Synthesis MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Personalized Peptide-based Vaccination for Treatment of Colorectal Cancer: Rational and Progress
Current Drug Targets 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis
Current Radiopharmaceuticals Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Synthesis and Anticancer Activity of Some 2-[3/4-(2-Substituted Phenyl-2- oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one Derivatives
Letters in Drug Design & Discovery Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Current Drug Targets The Recent Electrochemical Biosensor Technologies for Monitoring of Nucleic Acid Hybridization
Current Analytical Chemistry Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
Current Drug Metabolism Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention
Current Pharmaceutical Design Therapeutic Targets in Inflammatory Disease
Current Medicinal Chemistry Majra Honey Abrogated the Normal and Cancer Cells Proliferation Inhibition by Juniperus procera Extract and Extract/Honey Generated AgNPs
Anti-Cancer Agents in Medicinal Chemistry A Fluorescent Alkyllysophospholipid Analog Exhibits Selective Cytotoxicity Against the Hormone-Insensitive Prostate Cancer Cell Line PC3
Anti-Cancer Agents in Medicinal Chemistry